Prognostic and clinicopathological utility of PD-L2 expression in patients with digestive system cancers: A meta-analysis
•PD-L2, oneoftwoligandsfor PD-1, has already been detected in various cancers.•High PD-L2 overexpression indicates poor prognosis in digestive system cancers.•High PD-L2 overexpression is associated with lymphatic metastasis, tumor metastasis and histopathological stage. Programmed death ligand-2 (P...
Gespeichert in:
Veröffentlicht in: | International immunopharmacology 2020-11, Vol.88, p.106946-106946, Article 106946 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | •PD-L2, oneoftwoligandsfor PD-1, has already been detected in various cancers.•High PD-L2 overexpression indicates poor prognosis in digestive system cancers.•High PD-L2 overexpression is associated with lymphatic metastasis, tumor metastasis and histopathological stage.
Programmed death ligand-2 (PD-L2)has been detected in various cancers. However, its prognostic value in digestive system cancers (DSCs) remains unclear. Accordingly, this meta-analysis investigated the prognostic and clinicopathological utility of PD-L2 in patients with DSCs.
We systematically searched PubMed, EMBASE, Web of Science, ClinicalTrials.gov., Scopus, and Cochrane Library databases for eligible studies up to April 30, 2020. The hazard ratio (HR), odds ratio (OR), and corresponding 95% confidence interval (CI) of the outcomes were calculated.
Twenty two studies with 4886 patients were included in this meta-analysis. The pooled results showed that PD-L2 overexpression was significantly associated with poor overall survival (OS) (HR 1.470, 95% CI: 1.252–1.728, p |
---|---|
ISSN: | 1567-5769 1878-1705 |
DOI: | 10.1016/j.intimp.2020.106946 |